Back To TOP

Find Patient Assistance Patient Assistance Programs

We offer several options to help cover the cost of LUCENTIS® (ranibizumab injection) for your patients who are uninsured, have been denied coverage by their health plans, have concerns about co-pays or are worried about out-of-pocket expenses.

 


 

 

LUCENTIS Co-pay Card

The LUCENTIS Co-pay Card Program can help reduce the out-of-pocket costs for eligible LUCENTIS patients with commercial insurance, regardless of income.

 

 

 

 

 

Referrals to Co-pay Assistance Foundations

If privately or publicly insured patients have difficulty paying for their LUCENTIS co-pay, co-insurance or other expenses, LUCENTIS Access Solutions can refer them to a co-pay assistance foundation* supporting their disease state.

 

 

 

 

 

 

 

Genentech® Access to Care Foundation (GATCF)

GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive LUCENTIS free of charge. Learn more

 

* Genentech does not influence or control the operations of these co-pay assistance foundations, but LUCENTIS Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by LUCENTIS Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.
   
   
   
   

 

 

Learn More About
Lucentis
  • LEARN about treatment with LUCENTIS
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the LUCENTIS Co-pay Card can help with the out-of-pocket costs for LUCENTIS
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information

LUCENTIS Indications and Important Safety Information

INDICATIONS

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

  • Neovascular (wet) age-related macular degeneration (wAMD)
  • Macular edema following retinal vein occlusion (RVO)
  • Diabetic macular edema (DME)

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections or hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, headache, influenza, sinusitis, cough, and nausea.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full Prescribing Information